Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones. WATER ...
The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.
Arcus Biosciences and Gilead Sciences have reported promising Phase III results from their ARC-10 study of domvanalimab and ...
Arcus Biosciences unveiled data from a terminated late-stage study of its TIGIT and PD-1 drug combo that it says supports its decision to take the … ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback